Oncological safety and Reproductive morbidity after treatment for CIN


Accueil Abstract
Oncological safety and Reproductive morbidity after treatment for CIN Tuesday, December 4, 2018 Clinical Session • CS 04 • 10:15 AM > 11:45 AM • Oncological safety and Reproductive morbidity after treatment for CIN • Aud. III / IV 10:15 AM • CS 04-01 • Oncological safety and Reproductive morbidity in women with CIN and local treatment: what have learned from the epidemiological data? > M. Maria KYRGIOU 10:30 AM • CS 04-02 • National Data from England & Wales on Invasive cervical cancer incidence post-treatment and Risk of preterm birth > A. Alejandra Castanon 10:45 AM • CS 04-03 • Should we treat all women with CIN2 lesions? > I. Ilkka KALLIALA 11:00 AM • CS 04-04 • How can we use HPV biomarkers and decision support scoring systems to choose who to treat? > E. Evangelos PARASKEVAIDIS 11:15 AM • CS 04-05 • How can we explore the mechanisms leading to preterm birth after treatment and how should women be managed antenatally > A. Anita MITRA 11:30 AM • CS 04-06 • Discussion